COPY OF PAPERHS
ORIGINALLY FILED

03CC

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/058,151	
	Filing Date	01/25/2002	
	First Named Inventor	HORNBY, David et al.	
	Group Art Unit	1655	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	19	Attorney Docket Number	P-692

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	PTO-1449A (orig & dupl.); 2 pages Sequence Listing; Part 2 (copy of Notice to Comply); 1 CRF disk; Preliminary Amendment
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	John F. Brady Transgenomic, Inc.
Signature	 25732 PATENT & TRADEMARK OFFICE
Date	6/6/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: June 6, 2002			
Typed or printed name	Vivian Y. Buijter	Signature	
		Date	6/6/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



COPY OF PAPERS
ORIGINALLY FILED

Attorney Docket No. P-692

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HORNBY, David, et al:

Serial No. 10/058,151

Filing date: 01/25/2002

For: **MAXAM GILBERT G/A SEQUENCE
ANALYSIS BY DHPLC**

Art Unit No. 1655

Examiner: Not Yet Assigned

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL
(37 C.F.R. §1.8)**

Assistant Commissioner
for Patents
BOX MISSING PARTS
Washington, D.C. 20231

Attn: Customer Service Center
Initial Patent Examination Division

Sir:

I hereby certify that the following documents (including Postcard, Transmittal Form, Response to Notice to Comply With Requirements for Patent Application (2 pgs); Sequence Listing in Compliance with 37 C.F.R. §§1.821-1.825 (2 pgs); copy Notice to Comply with Requirements – Part 2 (2 pgs); CRF of Sequence Listing (1 disk); Preliminary Amendment (3 pgs); Information Disclosure Statement (2 pgs); and PTO-1449A (3 pgs – Orig. & Dupl.)), attached hereto, are being deposited with the United States Postal Service as first class mail in an envelope addressed to: the Assistant Commissioner for Patents, Box Missing Parts, Washington, D.C. 20231, Attn: Customer Service Center Initial Patent Examination Division, on June 6, 2002.

Vivian Y. Buijten

Typed Name of Person Mailing Correspondence


Signature of Person Mailing Correspondence



COPY OF PAPERS
ORIGINALLY FILED

5

Attorney Docket No. P-692

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HORNBY, David, et al.

Serial No. 10/058,151

Filing date: 01/25/2002

For: **MAXAM GILBERT G/A SEQUENCE
ANALYSIS BY DHPLC**

Art Unit No. 1655

Examiner: Not Yet Assigned

**RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Assistant Commissioner
For Patents
Washington, D.C.

Attn: Customer Service Center
Initial Patent Examination Division

Sir:

In response to the Notice to Comply With Requirements For Patent Applications mailed on 04/18/2002, Applicants submit herewith a Sequence Listing in compliance with 37 CFR §§1.821(g). A copy of the Notice to Comply (Part 2) is also enclosed.

The attached sequence complies with the sequence listing requirements as set forth in 37 CFR 1.821-1.825, and is appended to the specification by the attached Preliminary Amendment.


I hereby state that this Sequence Listing submission, filed in accordance with 37 CFR 1.821(g), does not include new matter.

I further state that the information recorded in computer readable form (CRF) found on the enclosed disk is identical to the written sequence listing attached hereto.

If anything further is required to put this application in order, the Examiner is invited to call the attorney of record at the number listed below.

Respectfully submitted,

Date: 6/6/02



John F. Brady

Attorney of Record
Registration No. 39,118

Telephone: (408) 514-3134
Facsimile: (408) 432-8910

Transgenomic, Inc.
2032 Concourse Drive
San Jose, CA 95131



**COPY OF PAPERS
ORIGINALLY FILED**

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/058,151	01/25/2002	David P. Hornby	P-692

CHRISTOPHER M. HOLMAN
TRANSGENOMIC, INC.
2032 CONCOURSE DRIVE
SAN JOSE, CA 95131



CONFIRMATION NO. 4854

FORMALITIES LETTER



OC000000007895372

Date Mailed: 04/18/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE